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1. INTRODUCTION
Recent technological advances have allowed for a more sophisticated understanding of the 
biology of tumors and an ability to generate massive data at an unprecedented pace. These 
advances now routinely allow for the assessment of genomics (DNA mutations and copy 
number alterations), transcriptomics (RNA expression levels), methylation profiles, and 
protein and phosphoprotein abundance to unravel the biologic underpinnings of various 
types of cancers. This information is now being combined with various imaging modalities, 
histopathology, clinical and patient characteristics, and treatment information to allow for a 
systems-based approach to understanding and characterizing cancer. With these advances, 
however, new challenges have emerged in how to acquire, store, catalog, analyze, and 
integrate these varying types of biologic data. This article will review examples of successful 
integration of genomic and biologic data, the current state of this research, issues 
surrounding access, extraction, collection, and curation of the genomic and biospecimens 
data. It will also suggest recommendations for standardizations and next steps to improve 
data availability.
With the completion of the human genome project and the subsequent inception and 
completion of The Cancer Genome Atlas (TCGA) project, the acquisition, storage, and 
subsequent availability of large-scale genomic, transcriptomic, and proteomic data has led to 
an accelerated pace of discovery and understanding of cancer.1–4 These data have led to the 
development of new, effective targeted agents, and ascertainment of this genomic and 
biospecimen data is now making its way into routine clinical practice.5 Indeed, multiple 
groups have recently published the findings of molecular tumor boards and these molecular 
data are now beginning to be used, including in the NCI-sponsored MATCH and IMPACT 
trials, the AACR-sponsored GENIE project, and ASCO-sponsored TAPUR trial, to inform 
clinical decision making as it relates to disease prognosis, effectiveness, therapeutic benefit, 
and mechanisms of treatment resistance.6–8 Other examples of the successful capture and 
annotation of genomic and biospecimen data include the Encyclopedia of DNA elements 
(ENCODE) project, and the International Cancer Genome Consortium (ICGC) project.
While the benefits of these molecular data in areas such as targeted drug development are 
increasingly clear, it is utility to predict radiation treatment toxicity and therapeutic response 
remains uncertain. While there are many reasons for this disparity, multiple initiatives 
including the REQUITE, RAPPER, Gene-PARE, RadGenomics, and canSAR projects are 
currently underway to collect, catalog, and make available this information.9–13 The success 
of these radiation-associated databases, and subsequent projects, however, will depend on 
the ability for these databases to be accessed, annotated, integrated, and updated.
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2. STATE OF THE RESEARCH
The acquisition and storage of genomic and biospecimen data is currently the exception, not 
the rule in radiation oncology clinical practice. When this information is gathered, it is 
usually for research purposes with variable translatability into clinical practice. While the 
reasons for this lack of sample collection are numerous, a major limitation to specimen 
collection is the requirement that it be prospectively incorporated into research and non-
research protocols. The collection and analysis of patient-derived biospecimens requires 
institutional review board (IRB) approval. This approval, in turn, is dependent on a clearly 
formulated rationale for collecting the information, and safeguards regarding the utilization 
of the information and protection of potentially identifiable information. This requires 
foresight, resources (monetary, staff, and space-related resources), and patient and physician 
buy in. Some groups have begun to address this challenge by creating “boilerplate” language 
that can be incorporated into the standard consenting process for any patient undergoing 
radiation treatment. This consent includes language that allows for the de-identified patient 
genomic data to be used for research purposes, and is easily included in prospective trials as 
well as the regular clinic workflow.14 Efforts to make this language and consent template 
more widely available are already underway.
An important area of radiation oncology research utilizing big data is radiogenomics, whose 
goal is the identification of genomic markers that are predictive for the development of 
outcomes resulting from cancer treatment with radiation.15 Work in radiogenomics has 
greatly benefited from creation of the Radiogenomics Consortium (RGC). The RGC was 
created in 2009 and is a cancer epidemiology consortium through the Epidemiology and 
Genomics Research Program of the NCI of the NIH.16 The RGC now has 225 member 
investigators located at 131 medical centers in 32 countries. The common goal of the RGC 
membership is to share biospecimens and data so as to achieve large-scale studies with 
increased statistical power to enable identification of relevant genomic markers. However, in 
order to accomplish this work and definitively discover and validate the critical genomic 
markers, access to the radiotherapy treatment information and long-term longitudinal follow-
up data reporting details such as outcomes must be obtained for large numbers of patients. 
The RGC does not maintain a centralized biorepository, but serves to facilitate the 
development of collaborations between investigators with similar research goals who have 
assembled cohorts and collected data that can be synthesized into one large study. Although 
the RGC has successfully assembled large cohorts to perform adequately powered studies, 
data harmonization remains a challenge for studies involving multiple patient cohorts treated 
with a variety of radiotherapy techniques and evaluated using multiple grading systems.15 
Although a proposed set of reporting requirements have been promulgated for research in 
radiogenomics, it would be advantageous if identical, or at least similar, case report forms 
were utilized for all radiogenomic research.17
An important example of the research projects launched by RGC investigators is the large 
multi-center REQUITE study (validation of predictive models and biomarkers of 
radiotherapy toxicity to reduce side-effects and improve quality-of-life in cancer survivors).
10
 REQUITE addresses the challenge of data heterogeneity that, as for other big data 
projects, requires harmonization of the different outcome measures and confounding 
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variables used in multiple cohorts. This study does not stipulate the radiotherapy protocols to 
be used but involves standardized case report forms across centers and countries to ensure 
data in identical categories are collected. The objectives of REQUITE are to: (a) Perform a 
multi-center, observational cohort study in which epidemiologic, treatment, longitudinal 
toxicity, and quality-of-life data are collected from approximately 5000 patients treated with 
radiotherapy for either breast, prostate, or lung cancer. (b) Produce a centralized biobank in 
which DNA is isolated from patients enrolled in the observational study and create a 
centralized data management system for secure collection, integration, mining, sharing, and 
archiving of all project data. A key aspect of the centralized database is that it includes 
pretreatment DICOM and DVH files. (c) Validate published SNP biomarkers of 
radiosensitivity and discover new variants associated with specific outcomes following 
radiotherapy, (d) validate clinical/dosimetric predictors of radiotherapy toxicity, and 
incorporate SNP biomarker data. (e) Design interventional trials to reduce long-term adverse 
cancer treatment effects. (f) Deliver interventional trial protocols using validated models 
incorporating biomarkers to identify patient sub-populations likely to benefit from 
interventions. (g) Serve as a resource exploitable for future studies exploring relationships 
between genetics and radiotherapy outcomes using developing technologies such as next-
generation sequencing. Those interested in becoming a member investigator of the RGC 
should contact Barry Rosenstein via email at barry.rosenstein@mssm.edu.
3. ACCESS AND EXTRACTION
With the decreasing costs and increasing availability of DNA and RNA sequencing, protein 
expression, and metabolite assessment, the amount of data generated per patient continues to 
increase. Despite the increase in the availability of these data, the subsequent capture of this 
information for anything other than to answer a specific research question or direct a clinical 
treatment decision remains extremely limited. While the reasons are myriad, the amount and 
complexity of the data is a major factor. It is now common for germline and somatic testing 
of patients and tumors to include at least some of the following assessment: DNA 
sequencing assessing germline and/or somatic mutations and copy number variation, single 
nucleotide polymorphism (SNP) assessment, RNA expression (either through RNA 
sequencing or gene expression microarrays, epigenomic assessment, proteomic assessment 
(through mass spectrometry or reverse phase protein lysate arrays), metabolomic 
assessment, and pathologic assessment of tumor samples (through immunohistochemical 
staining, flow cytometry assessment, or though the creation of institutional or multi-
institutional tissue microarrays (TMAs)). In addition to the sheer volume of biological 
molecules being assessed, the methods to analyze, interpret, and report the data are also 
varied. Issues of DNA sequencing read depth and sequence mapping for sequencing data 
continue to confound analyses of such data. Variation in algorithms utilized for DNA 
sequence mapping, variance, and allelic calls also contributes to the complexity and 
heterogeneity in type and quality of the data. One must decide whether to collect and store 
pre-processed vs raw data (i.e., normalized expression data vs CEL files for expression 
microarrays or FASTQ vs BAM files for DNA sequencing data). As an example, when raw 
DNA sequencing information is obtained, it usually comes from the DNA sequencer as 
FASTA or FASTQ files. FASTA and FASTQ format is based on simple text and contains the 
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raw data of each sequence read. For FASTA files, each sequence starts with a “>“ followed 
by the sequence name, a space, and, optionally, the description. In addition, a separate 
FASTA file will include the quality information of the given read sequences. FASTQ files 
were developed to provide a convenient way of storing the sequence and the quality scores 
in the same text-based file. It bears noting that depending on the sequencing technique 
(Sanger vs Illumina sequencing), different FASTQ files are generated based on the different 
ways in which quality is assessed between Sanger and Illumina sequencing. Because of this 
difference, the source of FASTQ data should be noted when storing the data as the encoding 
for the quality scores is different between Sanger and Illumina sequencing. In addition, 
paired reads are now routinely generated in which two reads are generated from the same 
single molecule to aid in sequence alignment. In this case (paired-reads data) two FASTQ 
files are created, one for the first read of the pairs and another one for the second, and the 
files should hold the reads exactly in the same order. Moving beyond simple read sequences 
FASTA or FASTQ files, alignment (SAM/BAM) and variation (VCF) files can also be 
created. Sequence Alignment Map (SAM) files were first created to store not only sequence 
and quality data (like in FASTQ files) but also mapping information for the sequences (i.e., 
where does each sequence align on the genome). To capture this more complex data, SAM 
files are tab based and include 11–12 fields that fill one line and may include a header. SAM 
can express the same information as FASTQ, but also includes mapping information (see 
https://samtools.github.io/hts-specs/SAMv1.pdf for more information). SAM is rarely used 
as the format for data storage, instead, files are stored in binary alignment mapping (BAM) 
format, which is a compact binary representation of SAM. It stores the same information, 
just more efficiently, and in conjunction with a search index, allows fast retrieval of 
individual records from the middle of the file. Because of its binary nature, BAM files are 
also much more compact than compressed FASTQ or FASTA files. Thus, when considering 
storage of genomic data one must decide upon file format storage (raw data in FASTQ vs 
processed and mappted data in BAM). Finally, there are data access (and limitations to 
access to preserve data security and patient anonymity) and extraction issues that have made 
the wide-spread availability of this information a challenge.
While there are no quick or easy solutions to these challenges, many groups have already 
grappled with these questions and found useful solutions. For example, in the case of the 
REQUITE trial, standardized case report forms were developed for data collection of 
epidemiological and patient characteristics. Collection of clinical/pathologic, physics, and 
treatment data was also standardized. Of critical importance, the full radiotherapy dose 
volume histogram was obtained for each subject, which provides substantial detailed 
dosimetric data. Data collection forms were provided in the different languages of the 
patients located in the multiple countries where they were enrolled into the study. Paper and 
web-based submission methods were provided in parallel. Submitted data underwent 
centralized quarterly quality control and plausibility checks for quality assurance according 
to a standardized quality assurance protocols. The database was enhanced to enable sample 
tracking in conjunction with the biobank information system, and empowered with user-
friendly interfaces to enable flexible data mining and data downloads in various formats. The 
database is only accessible to authorized persons via network and database passwords.
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4. COLLECTION AND CURATION
Important lessons can be learned from the challenges facing data extraction from health 
system-wide electronic medical records (EMR). Natural language processing (NLP) is part 
of a solution to extract data that are only available in free-text fields in EMRs. We are at a 
junction where development of a standardized format for collection and storage of genomics 
data (i.e., all BAM format) could potentially save significant resources in connecting 
genomics data to patient outcomes and dosimetric data. Independent validation is essential 
in the path toward the robust use of genomics data in clinical practice. By standardizing our 
clinical data collection, we can accelerate the discovery of which data are the most beneficial 
for specific classes of patients. One potential opportunity for increased capture and curation 
is to integrate with commercial (Flatiron) or organizational (CancerLinQ) platforms. These 
groups are already invested in data integration from EMR systems, and the increasing 
amount of clinically and commercially available genomic and biospecimen testing results 
may be extracted using these platforms. While these commercial and organizational 
platforms are still in their infancy, early integration into these groups may eliminate some of 
the challenges with later-stage integration. In addition, initial discussions with these groups 
could lead to standardization of collection and storage that could lessen, if not eliminate, 
subsequent challenges when the data are accessed/prepared for analysis. Certainly issues to 
consider in these initial discussions include: which format should be used to store data and 
whether raw or normalized data should be collected; should the data be normalized and if so 
which technique will be used; can EMRs be reconfigured to host and handle this genomic 
and biospecimen data; should biospecimen data be built into EMRs from radiation treatment 
unit vendors including Varian and Elekta (with Aria and Mosaiq); and how do we limit 
redundancy or discrepant data in these biospecimen data sets. While the answers to these 
questions are not immediately obvious, working group consensus and advocacy will allow 
for a clearer path forward as we seek to collect and curate genomic and biospecimen data.
5. SPECIFIC RECOMMENDATIONS FOR STANDARDIZATIONS
The utility of genomic and biospecimen data collection and utilization will depend heavily 
on the quality and completeness of the data collected. In an ideal world, these data would be 
automatically collected and seamlessly integrated into other databases of collected data 
(patient outcomes, comorbidities, toxicity, dosimetric, and treatment-related information, 
etc.). While this is unlikely to be reality in the near term, the following recommendations 
will allow for the gradual transition to this new reality. These recommendations include:
1. Pool genomics and bio-specimen analysis templates among centers active in 
genomics for clinical research so that common features are universally captured 
and similarly named for ease of extraction in the future. Appropriate batch effect 
corrections across sample acquisition and preparation sites would be necessary 
prior to data collation.18
2. Develop a standard nomenclature for data collection. Similar to the TG-263 task 
group, the formation of a similar task group to standardize genomic and 
biospecimen data nomenclature and reporting would significantly aid in this 
process.
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3. Harmonize the preferred format for standard fields to store genomics data within 
the hospital EMR with appropriate patient privacy safeguards built in. When 
housing within the EMR is not practical/feasible, uploading of genomics data 
with clinical outcomes and de-identified patient information into cBioPortal 
should be done (http://www.cbioportal.org).
4. Publish the recommendations such that individual institutions can request the 
major EMR vendors implement those standard fields. Concentrated and 
consistent pressure by end-users is likely to be more effective in implementing 
change than scatter shot, disjointed requests.
5. Identify institutions that would be able to perform validation of another 
institution’s results through a standard data query. Data standardization and 
completeness is a key limitation on integrating this more globally, and quality 
assurance measures and standardized operating procedures that are universally 
available and implemented will be key to subsequent data utilization and 
integration.
6. Following examples like TCGA, the Sharing of standardized analysis pipelines 
enable the communication of “best practices” for concordant, reproducible, and 
rigorous data analysis. Methods that enable the models to learn across 
institutional cohorts (i.e., distributed learning), rather than requiring the data to 
be centrally stored can create viable alternatives for effective data learning and 
interpretation while being cognizant of potential privacy concerns.19
6. RECOMMENDATIONS FOR NEXT STEPS
6.A. Develop and conduct a survey to determine the state, quantity, and quality of 
genomics and bio-specimens data in hospital EMRs
In order to successfully fix a problem, one must first effectively identify and define said 
problem. Before the integration of genomic and biospecimen data can become a reality, one 
must first understand the present barriers and limitations in real-world terms. A survey that 
includes academic and industry participants, data generators, and end users is critical to 
further identifying and then understanding the problem. The results of this initial survey will 
provide the basis for subsequent task group’s efforts as they seek to assist the integration of 
genomic and biospecimen data into the radiation oncology space. Involvement of health 
ethicists and geneticists as well as health policy experts will also be key in navigating issues 
surrounding the housing of genomic data within an EMR (including health insurance and 
employer privacy concerns as well as protocols for notification should actionable germline 
mutations be identified).
6.B. Share institutional best practices in data collection and storage and identify 
institutions, organizations, and companies who are willing to share current data templates
While an effort that begins by trying to capture all data at all institutions on all patients is 
unlikely to be successful in the near term, an effort that includes multi-institutional and 
multi-tiered (i.e., academic, organizational, and industry) collaborations is likely to help 
move the field towards this greater goal. Critical to the successful advocacy for the 
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integration of this data is receiving the support of large organizations already operating 
within this space. This includes dialogue with and endorsement from the American Society 
for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the 
NRG, the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the 
Global Alliance for Genomics in Health. As the sources for genomic and biospecimen data 
become increasingly available and complex, the inclusion of all parties associated with the 
data generation and usage in these collaborations will be important. By identifying those 
groups that both have an interest in the integration of these data and who “touch” the data on 
a daily basis, potential pitfalls will be more readily identified, and avoided, as this process 
continues.
6.C. Develop and publish the harmonized template to standardize data collection, 
generation, and analysis to facilitate connection to patient outcome and dosimetric data
As was noted earlier in the article, the formation of a task group to address issues pertaining 
to standardized collection and nomenclature will be crucial to the successful integration of 
genomic and biospecimen data into radiation oncology treatment paradigms. One of the 
mandates of this working group will be the publication of recommended templates and 
nomenclature standardization that will allow for the data to be universally accessed and 
utilized. The publication of uniform access requirements and sharing of “Best Practices for 
Data Collection” will be critical to the success of this project. Similar efforts for establishing 
standardized analysis templates (for variant interpretation, gene expression analysis, etc.) 
will be essential to create datasets amenable to sharing and joint mining in the context of 
corresponding imaging and outcome data.
7. FINAL CONSIDERATIONS
In addition to the previously noted “next steps”, integration “discovery” and “validation” 
pipelines into the workflow will enable the more effective utilization of these data in the 
future. By carefully considering the collection and partitioning of these “discovery” and 
“validation” cohorts, subsequent integration of findings utilizing genomics and biospecimen 
data will be expedited. Critical to this collection, curation, and storage is the need for data 
housing standardizations that are HIPAA compliant and removes patient identifiable 
information. This also includes the need to incorporate our medical ethicist colleagues to 
consider the ethical issues surrounding the acquisition, storage, and reporting of genomic 
and biospecimen data.
8. CONCLUSIONS
As we continue to translate the use of genomics data to guide treatment decisions for 
individual patients, we have an opportunity to accelerate this translation by developing and 
applying standard templates for data collection. By standardizing, they can be used to more 
robustly connect genomics and bio-specimen data directly to patient outcomes and 
dosimetric data. There is a lot of enthusiasm for how standardized nomenclature for organs-
at-risk and targets will accelerate the analysis of dose and patient outcomes (AAPM 
TG-263).20 Similar potential exists within the collection, annotation, and storage of genomic 
and biospecimen space. Initial steps should include: standardizing nomenclature for data 
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collection and harmonizing format of data collection and entry, pressuring EMR vendors to 
build genomic and biospecimen data collection into the EMR platform, and establishing a 
task group to generate specific guidelines governing the collection, analysis, and reporting of 
genomic data. Successful completion of these steps will allow genomic and biospecimen 
data to be integrated into future data analysis as we seek to improve treatment efficacy and 
limit normal tissue toxicity.
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